Bradley A Warady1, Janet N Iles2, Gema Ariceta3, Bastian Dehmel4, Guillermo Hidalgo5, Xun Jiang2, Benjamin Laskin6, Shahnaz Shahinfar6,7, Johan Vande Walle8, Franz Schaefer9. 1. Division of Pediatric Nephrology, Children's Mercy Kansas City, 2401 Gillham Road, 2MOB.17, Kansas City, MO, 64108, USA. bwarady@cmh.edu. 2. Amgen Inc., Thousand Oaks, CA, USA. 3. University Hospital Vall d' Hebron, Barcelona, Spain. 4. Amgen Europe GmbH, Zug, Switzerland. 5. Brody School of Medicine, East Carolina University, Greenville, NC, USA. 6. Children's Hospital of Philadelphia, Philadelphia, PA, USA. 7. S. Shahinfar Consulting Inc., Newtown Square, PA, USA. 8. Ghent University, Safedpedrug, Ghent, Belgium. 9. Heidelberg University Hospital, Heidelberg, Germany.
Abstract
BACKGROUND: This randomized phase 3 study evaluated the efficacy and safety of cinacalcet in children with secondary hyperparathyroidism (SHPT) receiving dialysis. METHODS: This study had double-blind and open-label phases. Eligible patients aged 6-< 18 years were randomized to cinacalcet (starting dose ≤ 0.20 mg/kg) or placebo. The primary endpoint was ≥ 30% reduction from baseline in mean intact parathyroid hormone (iPTH). Secondary endpoints included mean iPTH ≤ 300 pg/mL; percentage change from baseline in corrected total serum calcium, phosphorus, and calcium phosphorus product (Ca × P); and safety. RESULTS: The double-blind phase comprised 43 patients (cinacalcet, n = 22; placebo, n = 21). Nineteen months into the study, regulatory authorities were notified of a fatality; the study was subsequently terminated after a 14-month clinical hold. Before the hold, 12 patients (55%) on cinacalcet and four (19%) on placebo achieved the primary endpoint (p = 0.017), and 27% and 24%, respectively, achieved iPTH ≤ 300 pg/mL. The between-group differences (95% CI) in percentage changes for total serum calcium, phosphorus, and Ca × P were - 4% (- 9 to 1%), - 6% (- 21 to 8%), and - 10% (- 23 to 3%). The mean maximum actual weight-adjusted daily cinacalcet dosage administered was 0.99 mg/kg/day. Overall, 82% of patients on cinacalcet and 86% on placebo had ≥ 1 treatment-emergent adverse event; the most common were vomiting (32%, 24%, respectively), hypocalcemia (23%, 19%), nausea (18%, 14%), and hypertension (14%, 24%). CONCLUSIONS: Despite early termination, efficacy and safety outcomes observed with cinacalcet in children with SHPT on dialysis were consistent with adult observations, suggesting cinacalcet may meet an unmet medical need for this population.
RCT Entities:
BACKGROUND: This randomized phase 3 study evaluated the efficacy and safety of cinacalcet in children with secondary hyperparathyroidism (SHPT) receiving dialysis. METHODS: This study had double-blind and open-label phases. Eligible patients aged 6-< 18 years were randomized to cinacalcet (starting dose ≤ 0.20 mg/kg) or placebo. The primary endpoint was ≥ 30% reduction from baseline in mean intact parathyroid hormone (iPTH). Secondary endpoints included mean iPTH ≤ 300 pg/mL; percentage change from baseline in corrected total serum calcium, phosphorus, and calcium phosphorus product (Ca × P); and safety. RESULTS: The double-blind phase comprised 43 patients (cinacalcet, n = 22; placebo, n = 21). Nineteen months into the study, regulatory authorities were notified of a fatality; the study was subsequently terminated after a 14-month clinical hold. Before the hold, 12 patients (55%) on cinacalcet and four (19%) on placebo achieved the primary endpoint (p = 0.017), and 27% and 24%, respectively, achieved iPTH ≤ 300 pg/mL. The between-group differences (95% CI) in percentage changes for total serum calcium, phosphorus, and Ca × P were - 4% (- 9 to 1%), - 6% (- 21 to 8%), and - 10% (- 23 to 3%). The mean maximum actual weight-adjusted daily cinacalcet dosage administered was 0.99 mg/kg/day. Overall, 82% of patients on cinacalcet and 86% on placebo had ≥ 1 treatment-emergent adverse event; the most common were vomiting (32%, 24%, respectively), hypocalcemia (23%, 19%), nausea (18%, 14%), and hypertension (14%, 24%). CONCLUSIONS: Despite early termination, efficacy and safety outcomes observed with cinacalcet in children with SHPT on dialysis were consistent with adult observations, suggesting cinacalcet may meet an unmet medical need for this population.
Authors: Aadil Kakajiwala; Thomas O Jemielita; Lawrence Copelovitch; Mary B Leonard; Susan L Furth; Amy York; Maryjane Benton; Andrew N Hoofnagle; Kimberly Windt; Karen Merrigan; April Lederman; Michelle R Denburg Journal: Pediatr Nephrol Date: 2017-06-30 Impact factor: 3.714
Authors: Jill S Lindberg; Sharon M Moe; William G Goodman; Jack W Coburn; Stuart M Sprague; Wei Liu; Peter W Blaisdell; Robert M Brenner; Stewart A Turner; Kevin J Martin Journal: Kidney Int Date: 2003-01 Impact factor: 10.612
Authors: L Darryl Quarles; Donald J Sherrard; Stephen Adler; Steven J Rosansky; Laura C McCary; Wei Liu; Stewart A Turner; David A Bushinsky Journal: J Am Soc Nephrol Date: 2003-03 Impact factor: 10.121
Authors: Angela E Ballinger; Suetonia C Palmer; Ionut Nistor; Jonathan C Craig; Giovanni F M Strippoli Journal: Cochrane Database Syst Rev Date: 2014-12-09
Authors: Jun Oh; Rainer Wunsch; Martin Turzer; Malte Bahner; Paolo Raggi; Uwe Querfeld; Otto Mehls; Franz Schaefer Journal: Circulation Date: 2002-07-02 Impact factor: 29.690
Authors: Suetonia C Palmer; Ionut Nistor; Jonathan C Craig; Fabio Pellegrini; Piergiorgio Messa; Marcello Tonelli; Adrian Covic; Giovanni F M Strippoli Journal: PLoS Med Date: 2013-04-30 Impact factor: 11.069
Authors: Bradley A Warady; Eric Ng; Laura Bloss; May Mo; Franz Schaefer; Justine Bacchetta Journal: Pediatr Nephrol Date: 2020-05-04 Impact factor: 3.714
Authors: Ana Lúcia Cardoso Santos Abreu; Emília Maria Dantas Soeiro; Leonardo Gonçalves Bedram; Maria Cristina de Andrade; Renata Lopes Journal: J Bras Nefrol Date: 2021-12-03